Insights Into Breast Cancer 2020 Northeast

Perspectives from community physicians from the northeast region of the US on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents

Northeast – August 26, 2020

Faculty Chair

Joyce A. O’Shaughnessy, MD

Texas Oncology-Baylor Charles A. Sammons Cancer Center, TX, US

Example Report

Start discovering the insights

View Report


Treatment of HR-Positive Advanced Breast Cancer

  • Initial endocrine therapy: Single agent vs combination with CDK4/6 inhibitor
  • Targeted therapy for PIK3CA-mutated disease
  • Treatment of progressive disease: Choice of next-line endocrine therapy, impact of prior treatment, monotherapy vs combinations with targeted agents (eg, everolimus, CDK4/6 inhibitor [beyond progression?])
  • When to switch to chemotherapy, choice of initial and later-line treatment

Treatment of HER2-Positive Advanced Breast Cancer

  • Initial therapy: Is dual HER2 blockade the standard?
  • Treatment of progressive disease: TDM-1 vs other options
  • Next-generation anti-HER2 agents

Treatment of Triple-Negative Advanced Breast Cancer

  • Initial chemotherapy – preferred regimen, role of platinum compounds in practice, taxane selection (eg, nab-paclitaxel)
  • Later lines of chemotherapy – role of eribulin and other agents, impact of prior therapy
  • Role of PARP inhibitors – approach to germline and somatic BRCA mutation testing, current views on “BRCAness” and homologous recombination deficiency as biomarkers
  • Immunotherapy (± nab-paclitaxel)
  • Promising investigational targets and immunotherapy


  • A moderated virtual roundtable discussion focusing on treatment of breast cancer was held August 26, 2020
  • The group of advisors comprised 10 community oncologists from the northeast region of the US.
  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.